Amgen (AMGN) Competitors

Amgen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Amgen presently has a consensus price target of $387.93, suggesting a potential downside of 8.96%. Moderna has a consensus price target of $100.60, suggesting a potential downside of 55.55%. Given Amgen's stronger consensus rating and higher probable upside, research analysts clearly believe Amgen is more favorable than Moderna.

Amgen has a net margin of 22.95% compared to Moderna's net margin of -141.43%. Amgen's return on equity of 124.14% beat Moderna's return on equity.

76.5% of Amgen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amgen has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Moderna has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

In the previous week, Moderna had 19 more articles in the media than Amgen. MarketBeat recorded 53 mentions for Moderna and 34 mentions for Amgen. Amgen's average media sentiment score of 0.76 beat Moderna's score of 0.29 indicating that Amgen is being referred to more favorably in the media.

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Regeneron Pharmaceuticals presently has a consensus target price of $834.24, indicating a potential upside of 7.18%. Amgen has a consensus target price of $387.93, indicating a potential downside of 8.96%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.

In the previous week, Amgen had 18 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 34 mentions for Amgen and 16 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.00 beat Amgen's score of 0.76 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.4%. Regeneron Pharmaceuticals pays out 9.3% of its earnings in the form of a dividend. Amgen pays out 62.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat Regeneron Pharmaceuticals' return on equity.

Amgen has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat Vertex Pharmaceuticals' return on equity.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Amgen presently has a consensus target price of $387.93, indicating a potential downside of 8.96%. Vertex Pharmaceuticals has a consensus target price of $579.81, indicating a potential upside of 16.31%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Amgen.

In the previous week, Amgen had 23 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 34 mentions for Amgen and 11 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.84 beat Amgen's score of 0.76 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.9% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Amgen has a net margin of 22.95% compared to AbbVie's net margin of 9.80%. Amgen's return on equity of 124.14% beat AbbVie's return on equity.

AbbVie currently has a consensus target price of $277.18, suggesting a potential downside of 2.26%. Amgen has a consensus target price of $387.93, suggesting a potential downside of 8.96%. Given AbbVie's stronger consensus rating and higher probable upside, research analysts clearly believe AbbVie is more favorable than Amgen.

AbbVie has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Amgen has lower revenue, but higher earnings than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

In the previous week, AbbVie had 41 more articles in the media than Amgen. MarketBeat recorded 75 mentions for AbbVie and 34 mentions for Amgen. AbbVie's average media sentiment score of 0.83 beat Amgen's score of 0.76 indicating that AbbVie is being referred to more favorably in the media.

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.4%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.4%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 62.6% of its earnings in the form of a dividend. AbbVie has raised its dividend for 53 consecutive years and Amgen has raised its dividend for 14 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.